2:56 PM Dec 17, 2018

When drugs can’t go generic: Honoring our end of the contract with 'synthetic genericization'

The biopharma industry’s social contract with society relies on the idea that drugs eventually go generic and thereafter remain inexpensive. When that can’t happen, the contract breaks down -...

8:43 PM Dec 14, 2018

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead...

8:19 PM Dec 14, 2018

Extending Immunocore’s runway

The $100 million upfront payment from Immunocore Ltd.’s most recent deal with Roche's Genentech Inc. unit gives it enough cash to read out pivotal data from lead program IMCgp100, a catalyst...

5:34 PM Dec 14, 2018

FDA to facilitate access to unapproved drugs

FDA plans to launch a new program in 2019 that will help patients gain access to unapproved therapies. The agency will field telephone requests from physicians and patients, streamline the...

7:55 PM Dec 13, 2018

Gene therapy’s make or buy choice

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront...

1
2
3
4
5

Latest News

5:02 AM Dec 18, 2018

Erasca launches to target cancer drivers

Oncology company Erasca Inc. (San Diego, Calif.) launched Tuesday with a $42 million series A round and a...

5:00 AM Dec 18, 2018

Entrada raises $59M series A to take intracellular biologic into clinic

Entrada Therapeutics Inc. (Boston, Mass.) emerged from stealth Tuesday after raising $59 million in a...

11:06 PM Dec 17, 2018

China outlines adjuvant drug list

China’s National Health Commission announced plans to create a national adjuvant drug list and...

11:01 PM Dec 17, 2018

Gritstone showcases mass spec-based neoantigen discovery platform

Gritstone Oncology Inc. (NASDAQ:GRTS) unveiled the inner workings of its mass spectrometry-based...

5:01 PM Dec 17, 2018

China gives FibroGen its first approval for roxadustat

After over a decade of development, FibroGen Inc. (NASDAQ:FGEN) said China's National Medical Products...

3:39 PM Dec 17, 2018

Innovent diversifies pipeline with China rights to three Incyte compounds

Innovent Biologics Inc. (HKSE:1801) added three targets and a new modality to its pipeline following a...

3:26 PM Dec 17, 2018

Novo gets option to cardiovascular company Staten

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) received an option to acquire Staten Biotechnology B.V. (Nijmegen,...

2:38 PM Dec 17, 2018

China approves Junshi’s Tuoyi, first domestic anti-PD-1 mAb

China's National Medical Products Administration (NMPA) conditionally approved on Monday the first...

2:19 PM Dec 17, 2018

Downshifting CARs for better mileage

A study from Michel Sadelain's lab at the Memorial Sloan Kettering Cancer Center suggests that CARs with...

2:09 PM Dec 17, 2018

Management tracks: Vertex’s Graney joins Generation Bio

Tom Graney has left Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) as CFO to take on the same role at non-viral...

1:51 PM Dec 17, 2018

ACA ruling threatens biosimilars provisions

A federal district court ruling Friday that could strike down the entire Affordable Care Act threatens to...

7:34 AM Dec 17, 2018

Versant raises $700M across two funds

Versant Ventures has raised $700 million across two new funds. Versant Venture Capital VII closed at $600...

7:21 AM Dec 17, 2018

FDA picks Flatiron’s Abernethy for No. 2 spot

FDA has hired data scientist and oncologist Amy Abernethy of Flatiron Health Inc. for its No. 2 spot,...

4:02 AM Dec 17, 2018

Proteomics company Seer launches with $36M

Counting nanoparticle pioneer Omid Farokhzad, Robert Langer and Biogen Inc. (NASDAQ:BIIB) vet Philip Ma...

4:06 PM Dec 14, 2018

Shanghai Henlius up for Hong Kong IPO

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Friday to list on the Hong...

4:04 PM Dec 14, 2018

Firdapse re-catalyzes pricing debate

A decision by Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) to charge $375,000 a year for Firdapse...

4:04 PM Dec 14, 2018

J&J shares plummet following asbestos report

Johnson & Johnson (NYSE:JNJ) fell $14.84 (10%) to $133 on Friday, wiping out nearly $40 billion in...

4:02 PM Dec 14, 2018

BIO, PhRMA look to U.S.-Japan trade talks to shape pricing reforms

Forthcoming U.S-Japan trade negotiations could provide industry trade groups BIO and PhRMA a mechanism to...

3:39 PM Dec 14, 2018

FDA approves Celltrion's Herceptin biosimilar

FDA approved a BLA for Herceptin biosimilar Herzuma trastuzumab-pkrb from Celltrion Inc. (KOSDAQ:068270)...

3:37 PM Dec 14, 2018

Amgen pulls out of Advaxis immunotherapy deal

Advaxis Inc. (NASDAQ:ADXS) will continue to enroll patients in a Phase I trial of its ADXS-NEO program...

Down Up